top of page
Astraea in the Spotlight
Dr. Nurulain Zaveri - Invited speaker at the 8th annual Neuropsychiatric Drug Development Summit in Boston, MA
In her talk titled "Deciphering the Complexity of the Addiction Phenotype & Underlying Mechanisms of Substance Use Disorders" she will discuss the biological and genetic features associated with addiction, as well as evaluate how different drugs of abuse impinge upon reward circuits.
Dr. Nurulain Zaveri invited to speak at the Empowering Women in Organic Chemistry (EWOC) Conference, as a panelist on the topic of Empowering Your Choices.
Nicotine Drug Candidate
Dr. Nurulain T. Zaveri, PhD, FAAPS, is the first recipient of inaugural 2020 Alice E. Till Recognition for Advancement of Women in Pharmaceutical Sciences, from the American Association of Pharmaceutical Sciences (AAPS).
Dr. Zaveri is a Fellow of the AAPS, and a founding leader for the Women in Pharmaceutical Sciences community at AAPS.
Alice E. Till Recognition
"AT-121, a small molecule agonist of two opioid receptors, mediates analgesia without opioid-associated side effects in nonhuman primates" - Science Translational Medicine
A Promising Alternative to Opioid Pain Medications
Dr. Nurulain T. Zaveri, PhD
President and Chief Scientific Officer
​
AT 121
bottom of page